KRYXANA

This brand name is authorized in Nigeria.

Active ingredients

The drug KRYXANA contains one active pharmaceutical ingredient (API):

1	Ribociclib UNII TK8ERE8P56 - RIBOCICLIB
	Ribociclib is a selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6, resulting in 50% inhibition (IC50) values of 0.01 (4.3 ng/ml) and 0.039 μM (16.9 ng/ml) in biochemical assays, respectively. These kinases are activated upon binding to D-cyclins and play a crucial role in signalling pathways which lead to cell cycle progression and cellular proliferation.
	Read more about Ribociclib

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-100729	Tablet	KRYXANA 200MG FILM COATED TABLET TAB 200 mg 1 X 21	81 NF-PP-341708 KRYXANA 200MG FILM COATED TABLET Ribociclib Ribociclib 200mg; Tablet core: Microcrystalline cellulose; low-substituted hydroxypropylcellulose; crospovidone (Type A); colloidal silicon dioxide; magnesium stearate. Coating material: Polyvinyl alcohol (partially hydrolyzed); titanium dioxide (E171); iron oxide black (E172); iron oxide red (E172); talc; lecithin (soy) (E322); xanthan gum A4-100729 Drugs Imported Products 121 POM 1 10/25/2023 NOVARTIS NIGERIA LIMITED, LANDMARK BUILDING 52/54 ISAAC JOHN STREET IKEJA-GRA LAGOS LAGOS 2.34707E+12 arit.onwusah@novartis.com LEK PHARMACEUTICALS DD, VEROVSKOVA 57 LJUBLJANA SLOVENIA, Slovenia	31/01/2024

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EF02		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EF Cyclin-dependent kinase (CDK) inhibitors
Discover more medicines within L01EF02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A4-100729